Shots:
- The P-I/II (TWINPEAK) trial data assessed spevatamig alone & in combinations to treat advanced gastric, GEJ, pancreatic ductal or biliary tract adenocarcinomas in the US
- As of Dec 12, 2025, 107 pts received spevatamig alone or in combination; 42 with 1L mPDAC were treated with spevatamig + GnP, with spevatamig (2mg/kg, QW) data presented at ASCO GI’26 & 3mg/kg (QW) dose data still maturing
- In 1L mPDAC pts (n=15) receiving spevatamig (2mg/kg, QW) + GnP, DCR was 93%, ORR was 40% (6 had PR, with 1 pending confirmation), 6mos. PFS rate was 59% (mPFS: 7.3mos.) & 6mos. OS rate was 93% (mOS: 13.2mos.; still maturing), with responses observed in CLDN18.2 ≥10% pts (85% pts met threshold)
Ref: PRnewswire | Image: Phanes | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
